WO2009152346A3 - Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof - Google Patents

Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof Download PDF

Info

Publication number
WO2009152346A3
WO2009152346A3 PCT/US2009/047058 US2009047058W WO2009152346A3 WO 2009152346 A3 WO2009152346 A3 WO 2009152346A3 US 2009047058 W US2009047058 W US 2009047058W WO 2009152346 A3 WO2009152346 A3 WO 2009152346A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
phosphoinositide
compositions
kinase sirna
sirna
Prior art date
Application number
PCT/US2009/047058
Other languages
French (fr)
Other versions
WO2009152346A2 (en
Inventor
Frank Y. Xie
Original Assignee
Intradigm Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intradigm Corporation filed Critical Intradigm Corporation
Publication of WO2009152346A2 publication Critical patent/WO2009152346A2/en
Publication of WO2009152346A3 publication Critical patent/WO2009152346A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01153—Phosphatidylinositol-4,5-bisphosphate 3-kinase (2.7.1.153), i.e. phosphoinositide 3-kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides nucleic acid molecules that inhibit PI3K expression. Methods of using the nucleic acid molecules are also provided.
PCT/US2009/047058 2008-06-11 2009-06-11 Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof WO2009152346A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6072808P 2008-06-11 2008-06-11
US61/060,728 2008-06-11

Publications (2)

Publication Number Publication Date
WO2009152346A2 WO2009152346A2 (en) 2009-12-17
WO2009152346A3 true WO2009152346A3 (en) 2010-05-06

Family

ID=41091802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/047058 WO2009152346A2 (en) 2008-06-11 2009-06-11 Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2009152346A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45471A (en) * 2016-04-01 2019-02-06 Avidity Biosciences Llc PHOSPHATIDYLINOSITOL-3-KINASE NUCLEIC ACIDS AND THEIR USES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005091849A2 (en) * 2004-03-02 2005-10-06 The Johns Hopkins University Mutations of the pik3ca gene in human cancers
WO2007136758A2 (en) * 2006-05-19 2007-11-29 Board Of Regents, The University Of Texas System Sirna inhibition of p13k p85, p110, and akt2 and methods of use
WO2008109375A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
WO2009071082A2 (en) * 2007-12-03 2009-06-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of pik3ca expression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005091849A2 (en) * 2004-03-02 2005-10-06 The Johns Hopkins University Mutations of the pik3ca gene in human cancers
WO2007136758A2 (en) * 2006-05-19 2007-11-29 Board Of Regents, The University Of Texas System Sirna inhibition of p13k p85, p110, and akt2 and methods of use
WO2008109375A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
WO2009071082A2 (en) * 2007-12-03 2009-06-11 Santaris Pharma A/S Rna antagonist compounds for the modulation of pik3ca expression

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BRACHMANN SASKIA M ET AL: "Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 25, no. 5, 1 March 2005 (2005-03-01), pages 1596 - 1607, XP002484276, ISSN: 0270-7306 *
DATABASE Geneseq [online] 13 November 2008 (2008-11-13), "Human PIK3CA mRNA target sequence for mdRNA, SEQ ID:1368.", XP002547686, retrieved from EBI accession no. GSN:ATM52333 Database accession no. ATM52333 *
DATABASE Geneseq [online] 15 December 2005 (2005-12-15), "Human phosphatidylinositol 3-kinase DNA forward PCR primer SEQ ID No:140.", XP002547684, retrieved from EBI accession no. GSN:AED31756 Database accession no. AED31756 *
DATABASE Geneseq [online] 28 December 2007 (2007-12-28), "Viral regulatory miRNA SEQ ID NO 149125.", XP002547685, retrieved from EBI accession no. GSN:AJI96804 Database accession no. AJI96804 *
DATABASE PROBE [online] NCBI; 14 September 2006 (2006-09-14), "Small hairpin RNA (shRNA) probe for Homo sapiens gene phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA)", XP002547738, retrieved from NCBI Database accession no. Pr006104574.1 *
KIM IN-AH ET AL: "Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.", CANCER RESEARCH 1 SEP 2005, vol. 65, no. 17, 1 September 2005 (2005-09-01), pages 7902 - 7910, XP002547683, ISSN: 0008-5472 *
LEE J S ET AL: "Stable gene silencing in human monocytic cell lines using lentiviral-delivered small interference RNA", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 279, no. 10, 5 March 2004 (2004-03-05), pages 9379 - 9388, XP003004856, ISSN: 0021-9258 *
ZHANG LIN ET AL: "RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer.", CANCER BIOLOGY & THERAPY DEC 2004, vol. 3, no. 12, December 2004 (2004-12-01), pages 1283 - 1289, XP002547682, ISSN: 1538-4047 *

Also Published As

Publication number Publication date
WO2009152346A2 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
WO2009108217A3 (en) Compositions comprising k-ras sirna and methods of use
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2009114475A3 (en) Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
WO2009002440A3 (en) Compositions comprising human egfr-sirna and methods of use
WO2010018563A3 (en) Compositions and methods for the prognosis of lymphoma
WO2014028429A3 (en) Enzymes and polymerases for the synthesis of rna
WO2008134761A3 (en) Modification of biological targeting groups for the treatment of cancer
WO2013163190A8 (en) Dna-pk inhibitors
WO2010120853A3 (en) Methods and compositions to detect and differentiate small rnas in rna maturation pathway
WO2009100320A3 (en) Bicyclic cyclohexitol nucleic acid analogs
ATE502122T1 (en) CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
GEP20125652B (en) cMET INHIBITORS
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2009077471A3 (en) Azolylmethyloxiranes, use thereof and agents containing the same
WO2010011331A3 (en) Compositions and methods related to sirt1 function
WO2010068292A8 (en) Azaindole derivatives as kinase inhibitors
WO2009114724A3 (en) COMPOSITIONS COMPRISING NUCLEAR FACTOR-KAPPA B (NF-ĸB) SIRNA AND METHODS OF USE
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2008092099A8 (en) Compositions and methods for treating hematopoietic malignancies
WO2009143371A3 (en) COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF
WO2011130426A3 (en) Compositions and methods for treatment of melanoma
WO2009047634A3 (en) Aqueous formulations of acetaminophen for injection
WO2013052006A8 (en) Parp-1 inhibitors
WO2009152387A3 (en) Compositions comprising cmyc sirna and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09763634

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09763634

Country of ref document: EP

Kind code of ref document: A2